Open AccessComparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor
Author(s) -
Н. А. Петунина,
Анна Леонтьевна Терехова,
Е. В. Гончарова
Publication year - 2016
Publication title -
saharnyj diabet
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.155
H-Index - 12
eISSN - 2072-0378
pISSN - 2072-0351
DOI - 10.14341/dm7949
Subject(s) - canagliflozin , sitagliptin , medicine , quality of life (healthcare) , diabetes mellitus , type 2 diabetes mellitus , type 2 diabetes , clinical trial , weight loss , physical therapy , intensive care medicine , endocrinology , nursing , obesity
The article investigates the value of canagliflozin in the management of type 2 diabetes mellitus from the perspective of a clinically-based patient-centred approach. It focusses on the outcomes of a 52-week double-blind, active-controlled study. The results of this clinical trial demonstrate that canagliflozin, which provides significant weight loss ability, improves the quality of life and satisfaction with physical and emotional health in patients with diabetes compared with sitagliptin.